EUVIMEDEUVIMED entdecken
Beobachtungsstudie

G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe

Giada Acciaroli, Christopher G Parkin iD, Roy Thomas, Jennifer Layne, Gregory J Norman, Keri Leone

Diabetic Medicine · 2023-06 · 40 (6)

DOI: 10.1111/dme.15093 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetic Medicine, online erschienen am 05.04.2023. Verfasst von Giada Acciaroli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dexcom Inc., 6310 Sequence Drive, San Diego, California, 92121, USA. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Dexcom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Current continuous glucose monitoring (CGM) devices provide features that alert individuals with diabetes about their current and impending adverse glycaemic events. The use of these features has been associated with glycaemic improvements. However, how these features are utilised under real‐world conditions has not been well studied. We queried a large database to quantify utilisation of the Dexcom G6 system features and how utilisation impacted glycaemic outcomes within a cohort of European users.

Methods

This 6‐month retrospective, observational, large database analysis utilised anonymised data from a sample of 47,784 Europe‐based G6 users. Primary outcome measures were associations between utilisation and customisation of High/Low threshold alerts, ‘urgent low soon’ (ULS) alert, and established CGM metrics.

Results

Users in the Germany, Austria, Switzerland region ( n = 20,257), the Nordic countries ( n = 10,314), United Kingdom ( n = 9006), Italy ( n = 4747), France ( n = 2130) and Spain (1330) were included. All alert features were utilised by >75% of the cohort across all regions/countries and age groups. Enabling the Low alert and ULS alert was associated with lower percentage of time below range compared to disabling the Low alert ( p < 0.001). Enabling the High alert was associated with higher percentage of time in range (%TIR) and lower percentage of time above range (%TAR) %TAR compared to disabling the High alert ( p < 0.001). Paediatric patients and older adults tended to set a higher threshold for High/Low alerts, while younger adults tended to use lower threshold values for High/Low alerts.

Conclusions

Individuals who utilised the Dexcom G6 features showed better glycaemic control, particularly among those who utilised more sensitive High alert and Low alert settings, than users who did not utilise the system features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 1HumansChildAgedBlood Glucose Self-MonitoringRetrospective StudiesEurope

Stichwörter der Autor:innen

%TAR%TBR%TIRalertscontinuous glucose monitoringrtCGMsafety

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Dexcom Inc., 6310 Sequence Drive, San Diego, California, 92121, USA.
  • CGParkin Communications, 2675 Windmill Pkwy, Ste.2721, Henderson, Nevada, 89074, USA.

ORCID-Profile: Christopher G Parkin

Förderung

  • Dexcom

Zitieren

APA

Acciaroli, G., Parkin, C. G., Thomas, R., Layne, J., Norman, G. J., & Leone, K. (2023). G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe. Diabetic Medicine, 40(6). https://doi.org/10.1111/dme.15093

Vancouver

Acciaroli G, Parkin CG, Thomas R, Layne J, Norman GJ, Leone K. G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe. Diabetic Medicine. 2023;40(6). doi:10.1111/dme.15093

BibTeX
@article{Acciaroli2023,
  author = {Acciaroli, Giada and Parkin, Christopher G and Thomas, Roy and Layne, Jennifer and Norman, Gregory J and Leone, Keri},
  title = {G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe},
  journal = {Diabetic Medicine},
  year = {2023},
  volume = {40},
  number = {6},
  doi = {10.1111/dme.15093}
}
Kostenlos starten →